Erythropoietin Resistance in Patients with Chronic Kidney Disease: Current Perspectives

Anemia is a frequent complication of chronic kidney disease, and its primary cause is erythropoietin deficiency. After diagnosis, treatment begins with administration of an erythropoiesis-stimulating agent (ESA). However, some patients present with resistance to ESA, which needs to be reversed, as i...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos, Elton Jonh Freitas, Dias, Raimunda Sheyla Carneiro, Lima, Janielle Ferreira de Brito, Salgado Filho, Natalino, Miranda dos Santos, Alcione
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549651/
https://www.ncbi.nlm.nih.gov/pubmed/33116754
http://dx.doi.org/10.2147/IJNRD.S239151
Descripción
Sumario:Anemia is a frequent complication of chronic kidney disease, and its primary cause is erythropoietin deficiency. After diagnosis, treatment begins with administration of an erythropoiesis-stimulating agent (ESA). However, some patients present with resistance to ESA, which needs to be reversed, as it can increase the risk of death in patients with kidney disease. Therefore, we provide a discussion of the current literature regarding the factors that can modify the response to this class of drugs and the strategies that can be considered to optimize the benefits of treating anemia.

Ejemplares similares